Envestnet Asset Management Inc Supernus Pharmaceuticals, Inc. Transaction History

Envestnet Asset Management Inc

$302 Billion
Q3 2024

A detailed history of Envestnet Asset Management Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 56,475 shares of SUPN stock, worth $2.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

56,475

Previous 59,135 4.5%

Holding current value

$2.12 Million

Previous $1.58 Million 11.32%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$25.77 - $35.16 $68,548 - $93,525	-2,660 Reduced 4.5%	56,475 $1.76 Million
Q2 2024 Aug 08, 2024	SELL	$25.99 - $33.85 $759,245 - $988,860	-29,213 Reduced 33.07%	59,135 $1.58 Million
Q1 2024 May 13, 2024	BUY	$27.11 - $35.17 $341,694 - $443,282	12,604 Added 16.64%	88,348 $3.01 Million
Q4 2023 Feb 13, 2024	SELL	$22.72 - $29.68 $85,972 - $112,309	-3,784 Reduced 4.76%	75,744 $2.19 Million
Q3 2023 Nov 13, 2023	SELL	$27.57 - $32.91 $112,430 - $134,206	-4,078 Reduced 4.88%	79,528 $2.19 Million
Q2 2023 Aug 04, 2023	SELL	$29.91 - $38.73 $11.2 Million - $14.4 Million	-372,809 Reduced 81.68%	83,606 $2.51 Million
Q1 2023 May 11, 2023	BUY	$34.93 - $42.03 $12.9 Million - $15.5 Million	369,806 Added 426.98%	456,415 $16.5 Million
Q4 2022 Feb 07, 2023	BUY	$31.09 - $37.88 $239,548 - $291,865	7,705 Added 9.77%	86,609 $3.09 Million
Q3 2022 Nov 10, 2022	BUY	$28.79 - $35.41 $180,916 - $222,516	6,284 Added 8.65%	78,904 $2.67 Million
Q2 2022 Aug 03, 2022	BUY	$25.33 - $34.25 $24,722 - $33,428	976 Added 1.36%	72,620 $2.1 Million
Q1 2022 May 04, 2022	BUY	$28.51 - $32.9 $94,510 - $109,063	3,315 Added 4.85%	71,644 $2.32 Million
Q4 2021 Feb 04, 2022	BUY	$26.37 - $34.22 $354,834 - $460,464	13,456 Added 24.52%	68,329 $1.99 Million
Q3 2021 Oct 07, 2021	BUY	$23.54 - $31.39 $143,570 - $191,447	6,099 Added 12.5%	54,873 $1.46 Million
Q2 2021 Aug 04, 2021	BUY	$26.72 - $33.19 $261,268 - $324,531	9,778 Added 25.07%	48,774 $1.5 Million
Q1 2021 May 04, 2021	BUY	$24.15 - $31.45 $607,203 - $790,747	25,143 Added 181.5%	38,996 $1.02 Million
Q4 2020 Feb 02, 2021	BUY	$17.7 - $25.81 $72,056 - $105,072	4,071 Added 41.62%	13,853 $349,000
Q3 2020 Oct 09, 2020	SELL	$20.2 - $25.05 $14,968 - $18,562	-741 Reduced 7.04%	9,782 $204,000
Q2 2020 Jul 08, 2020	SELL	$17.09 - $24.89 $9,792 - $14,261	-573 Reduced 5.16%	10,523 $250,000
Q1 2020 Apr 23, 2020	SELL	$14.45 - $24.69 $75,573 - $129,128	-5,230 Reduced 32.03%	11,096 $200,000
Q4 2019 Feb 11, 2020	SELL	$19.93 - $29.13 $217,396 - $317,750	-10,908 Reduced 40.05%	16,326 $387,000
Q3 2019 Oct 17, 2019	SELL	$25.47 - $33.37 $276,807 - $362,665	-10,868 Reduced 28.52%	27,234 $748,000
Q2 2019 Aug 02, 2019	SELL	$29.96 - $38.87 $16,238 - $21,067	-542 Reduced 1.4%	38,102 $1.26 Million
Q1 2019 May 10, 2019	BUY	$32.77 - $41.99 $30,148 - $38,630	920 Added 2.44%	38,644 $1.35 Million
Q4 2018 Feb 13, 2019	BUY	$30.84 - $49.51 $1.16 Million - $1.87 Million	37,724 New	37,724 $1.25 Million
Q3 2018 Nov 14, 2018	SELL	$42.7 - $56.55 $657,836 - $871,209	-15,406 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$44.1 - $59.85 $35,544 - $48,239	-806 Reduced 4.97%	15,406 $922,000
Q1 2018 May 09, 2018	SELL	$37.15 - $46.9 $1.95 Million - $2.46 Million	-52,387 Reduced 76.37%	16,212 $743,000
Q4 2017 Feb 20, 2018	BUY	$36.4 - $42.6 $71,489 - $83,666	1,964 Added 2.95%	68,599 $2.73 Million
Q3 2017 Nov 13, 2017	SELL	$36.75 - $49.65 $144,868 - $195,720	-3,942 Reduced 5.59%	66,635 $2.67 Million
Q2 2017 Aug 14, 2017	BUY	N/A	70,577	70,577 $3.04 Million

Others Institutions Holding SUPN

# of Institutions

279

Shares Held

60.6M

Call Options Held

27.7K

Put Options Held

11.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.01B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Account

Envestnet Asset Management Inc Supernus Pharmaceuticals, Inc. Transaction History